Shree Ganesh Biotech (India) Ltd

Dematerialisation/rematerialisation status

• The securities in the certificates have been listed on the stock exchanges.
• The certificates were mutilated and cancelled, with the depository's name substituted as registered owner.
• No physical certificates were received for demat during the period.

Financial Performance 📊

• Q3 FY2026 standalone revenue from operations: ₹69.81 lakh, down from ₹76.74 lakh in Q2 FY2026.
• Nine months ended Dec 31, 2025 revenue: ₹1,441.18 lakh vs ₹1,995.18 lakh in prior year period.
• Q3 FY2026 total income: ₹106.90 lakh, down from ₹117.75 lakh in Q2 FY2026.
• Nine months total income: ₹1,471.60 lakh vs ₹2,092.76 lakh in prior year period.
• Q3 FY2026 profit after tax: ₹32.23 lakh vs ₹1.41 lakh in Q2 FY2026; nine months PAT: ₹77.17 lakh vs ₹133.29 lakh prior year.
• Basic and diluted EPS for Q3 FY2026: ₹0.01 per share; nine months EPS: ₹0.02 per share.

Expenses & Taxation

• Q3 FY2026 total expenses: ₹74.67 lakh, down from ₹116.34 lakh in Q2 FY2026.
• Nine months total expenses: ₹1,394.43 lakh vs ₹1,959.47 lakh in prior year period.
• No tax expense recognized in Q3; provision for taxation to be made at year-end.

Audit & Compliance

• Results are unaudited standalone, reviewed by audit committee, with limited statutory auditor review.
• Auditor's review report found no material misstatement or disclosure issues.
• No exceptional or extraordinary items reported in quarter or nine months.

Business Model & Segments

• Company operates in a single reportable segment as per Ind AS 108.

Financial Performance

• Approved unaudited standalone financial results for quarter and nine months ended December 31, 2025.
• Total income for nine months ended December 31, 2025 was ₹404.54 lakh; profit after tax ₹66.34 lakh.
• Revenue from operations for nine months ended December 31, 2025 stood at ₹284.92 lakh.
• Expenses for nine months ended December 31, 2025 totaled ₹338.20 lakh.
• Earnings per share (basic and diluted) for quarter ended December 31, 2025 was ₹0.01.
• No exceptional items reported for the period.

Governance & Compliance ️

• Provision for taxation to be made at year-end; no tax expense recognized for quarter ended December 31, 2025.
• Statutory auditors conducted limited review and reported no material misstatements or qualifications.
• Financial results prepared as per Indian Accounting Standard 34 (Interim Financial Reporting).
• Company has a single reportable segment as per Ind AS 108.

Capital Structure

• Paid-up equity share capital remained ₹3,986.24 lakh with face value ₹1 per share.

Board Decisions ️

• Board meeting held on January 29, 2026, approved the financial results.

🗓️ Meeting Details

• Board meeting scheduled for Thursday, 29 January 2026.

📊 Financial Performance

• Approval of unaudited financial results for quarter and nine months ended 31 December 2025.